- Home
- VBIX vs BTAI Comparison
VBIX vs BTAI Comparison
Compare VBIX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VBIX | BTAI |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Israel | United States |
| Employees | 21 | 29 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 34.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | VBIX | BTAI |
|---|---|---|
| Price | $3.60 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 25.6K | ★ 600.4K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $1.01 |
| 52 Week High | $6.31 | $8.08 |
Technical Indicators
Market Signals| Indicator | VBIX | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 88.05 | 45.26 |
| Support Level | $2.54 | $1.02 |
| Resistance Level | $3.70 | $1.26 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 98.39 | 21.67 |
Price Performance
Historical ComparisonAbout VBIX Viewbix Inc.
ViewBix Inc operates in the field of digital advertising. The company operates in single segment, the search segment that develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.